-
Featured
Ultrasound Therapy Yields Promising Results for Localized Prostate Cancer
At the American Urological Association's 2019 Annual Meeting, researchers presented the findings of a study on the effects transurethral ultrasound ablation (TULSA), a novel minimally invasive procedure that can reduce prostate size and prostate-specific antigens in patients with localized prostate cancer.
-
Featured
Improving the Safety of Vena Caval Thrombectomy in Kidney Cancer with Tumor Thrombus Team Approach
Complete removal of a tumor thrombus resulting from venous tumor invasion is essential for eliminating the cancer in patients with advanced renal cell carcinoma (RCC). A multispecialty tumor thrombus team within an integrated practice can improve the safety of this intricate and extensive procedure.
-
Featured
Laterality of Renal Cell Carcinoma Predicts Survival in Certain Patient Subgroups
Patients with right-sided renal cell carcinoma are significantly more likely to have favorable clinicopathological features than patients with left-sided disease, and they have significantly better cancer-specific survival within certain subgroups.
-
Potential Strategy Identified for Treating Bone-Metastatic Clear Cell RCC
Shenglin Mei, PhD, and colleagues used single-cell RNA sequencing to construct a transcriptomic atlas of cells in the microenvironment of human bone-metastatic clear cell renal cell carcinoma and identified a subpopulation of mesenchymal stromal cells as a potential therapeutic target.
-
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Douglas M. Dahl, MD, Jason A. Efstathiou, MD, DPhil, and colleagues determined that in patients with muscle-invasive bladder cancer who were not candidates for cystectomy or cisplatin, maximum tumor resection and chemoradiation were associated with high response rates and five-year overall survival rates of 25% to 38%.
-
Urine Test Validated for Diagnosis, Surveillance and Risk Prediction in Urothelial Carcinoma
In a multicenter case–control study, Massachusetts General Hospital researchers validated a new urinary comprehensive genomic profiling test, which requires only a urine specimen, for detecting urothelial carcinoma in patients with hematuria and predicting recurrence before clinical signs or symptoms appear.
Mass General Cancer Center Contributors
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
David T. Miyamoto, MD, PhD
Attending Radiation Oncologist, Department of Radiation Oncology, Massachusetts General Hospital, Investigator, Center for Cancer Research, Mass General Cancer Center, Assistant Professor of Radiation Oncology, Harvard Medical School
Recent Article
High MRE11 in Muscle-invasive Bladder Tumors Linked to Better Survival After Chemoradiation -
Douglas M. Dahl, MD
Chief, Division of Urologic Oncology, Vice-Chair, Department of Urology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center, Associate Professor of Surgery (Urology), Harvard Medical School
Recent Article
Multiparametric MRI Is Often False-Negative for Clinically Significant Prostate Cancer
-
-
Jason A. Efstathiou, MD, DPhil
Vice-Chair, Faculty & Academic Affairs, Director, Genitourinary Division, Department of Radiation Oncology, Massachusetts General Hospital, Co-Director, The Claire and John Bertucci Center for Genitourinary Cancers, Mass General Cancer Center, Professor of Radiation Oncology, Harvard Medical School
Recent Article
Less Aggressive Protocol Suitable for Muscle-invasive Bladder Cancer in Noncystectomy Candidates
Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program
Physicians in the Mass General Bladder, Kidney, Penile, Prostate and Testicular Cancer Program specialize in using advanced surgical therapies and minimally invasive procedures to treat male and female genitourinary cancers.
